Research and Markets (http://www.researchandmarkets.com/research/4301f4/european_lifestyle)
has announced the addition of Frost & Sullivan's new report "European
Lifestyle Disorders Therapeutics Market" to their offering.
“With the increase in demand for
new therapies, the degree of competition among pharmaceutical companies
is also intensifying”
This research service deals with market drivers, restraints, market
trends, competitive structure, revenues and market attractiveness
analysis of the European lifestyle disorders therapeutics market.
This Frost & Sullivan research service titled European
Lifestyle Disorders Therapeutics Market provides an insight into
industry challenges and market drivers and restraints besides including
strategic recommendations. In this research, Frost & Sullivan's expert
analysts thoroughly examine the following markets: lifestyle disorders
therapeutics, obesity therapeutics and erectile dysfunction
therapeutics. Industry challenges, market drivers and restraints,
revenue forecasts, brand analysis and competitive structure are provided
for all these markets together with strategic recommendations.
Market Overview
Development of Newer Therapies to Treat Lifestyle Disorders Critical to
Advancing the European
Lifestyle Disorders Therapeutics Market
Increasing genomic knowledge will lead to the development of improved
therapies to treat lifestyle disorders. In the near future, the European
lifestyle disorders therapeutics market is set to witness enhanced
therapies and novel drugs to treat such conditions and reduce the risk
of co-morbidities.
"The future is likely to witness improved therapies and novel drugs to
treat lifestyle disorders and lower the risk of co-morbidities," notes
the analyst of this research. "However, the lack of investment in the
current financial climate has dampened the development of newer
therapies and technologies, while presenting a major challenge for small
biotechnology companies." As preventive care and personalised medicine
come to the fore, more companies are venturing into lifestyle disorders
therapeutics. These new developments are likely to present attractive
investment opportunities to large biopharmaceutical companies.
Clear Reimbursement Policies and Harmonisation of Regulations Necessary
to Sustain Market Expansion